1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Jia Jie Biomedical Co., Ltd.

Jia Jie Biomedical Co., Ltd.

TTPEX:4109
10.95
TWD
-0.05
(-0.45%)
0.03EPS
433.24P/E
1.34BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.81
8.49
11.32
8.84
7.37
5.68
4.84
3.79
2.65
3.48
3.64
5.48
4.17
4.34
Basic EPS, GAAP
0.36
0.3
0.54
0.16
-3.28
0.03
-0.35
-0.45
0.06
-0.06
1.58
2.16
0.43
0.03
Free Cash Flow per Basic Share
-0.37
0.17
-2.73
-1.53
-0.24
-0.3
0.31
0.36
0.03
-0.29
-0.14
0.25
-0.55
-0.44
Dividend per Share
0.36
0.29
0.2
0.21
0.09
- -
- -
- -
- -
- -
- -
0.5
0.51
- -
Book Value per Share
12.57
13.02
13.43
13.2
9.74
9.99
11.11
9.95
9.93
9.83
11.45
13.12
14.18
13.69
Tangible Book Value per Share
11.83
12.37
12.82
12.62
9.64
9.98
11.09
9.94
9.71
9.6
11.23
12.37
13.56
13.06
Basic Weighted Avg Shares
61
69
70
71
71
71
71
71
91
91
91
98
116
119
Sales/Revenue/Turnover
598
589
797
626
522
402
343
270
242
318
333
537
485
515
Operating Margin (%)
0.59
0.89
12.26
6.03
-11.35
-10.86
-7.12
-17.88
-0.51
-4.53
-19.98
6.19
0.14
-2.24
Depreciation Expense
28
23
21
20
21
16
18
16
13
17
15
16
18
20
Net Income, GAAP
22
20
38
12
-232
2
-24
-32
5
-5
144
211
50
3
Effective Tax Rate (%)
- -
21.24
39.59
46.48
- -
88.22
- -
- -
3.61
- -
- -
4.14
12.94
- -
Profit Margin (%)
3.69
3.47
4.74
1.86
-44.48
0.62
-7.14
-11.81
2.2
-1.72
43.32
39.36
10.35
0.6
Working Capital
245
147
103
92
-204
36
48
300
258
244
100
231
404
439
LT Debt
22
76
251
276
24
11
19
2
3
1
1
2
- -
66
Total Equity
893
957
983
963
700
714
695
908
935
924
1,070
1,359
1,714
1,656
Return on Invested Capital (%)
- -
0.38
4.58
1.37
- -
-0.45
- -
- -
-0.1
- -
- -
2.53
0.04
- -
Return on Capital (%)
- -
3.25
3.02
0.66
- -
0.51
- -
- -
0.61
- -
- -
16.5
3.11
- -
Return on Common Equity (%)
2.89
2.31
4.03
1.23
-28.56
0.35
-3.49
-3.98
0.59
-0.61
14.82
17.78
3.33
0.19

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
53
2
26
LT Borrowings
- -
70
66
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
119
119
Market Capitalization
1,840
1,514
1,342

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
574
596
592
Cash, Cash Equivalents & STI
482
504
500
Accounts Receivable, Net
45
38
47
Inventories
28
34
30
Total Current Liabilities
171
146
153
Payables & Accruals
- -
- -
- -
ST Debt
53
2
26
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.14%
14.15%
26.1%
Free Cash Flow
-210.79%
-364.23%
-359.52%
Net Income, GAAP
-640.95%
-616.79%
-76.22%
Sales/Revenue/Turnover
-1.97%
15.45%
-9.62%
Total Cash Common Dividend
- -
- -
20.26%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
160
151
95
130
537
2025
133
106
113
134
485
2026
135
133
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
2.17
0.03
-0.19
2.16
2025
0.12
-0.01
0.09
0.23
0.43
2026
0.15
-0.44
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.51
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Chuan Tseng
Full Time Employees
61
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 61, Jiuru 1st Road Kaohsiung City KH Taiwan 807
IPO Date
Jan 2, 2002
Website
jiajiebio.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Jia Jie Biomedical Co., Ltd. is a Taiwan-based company founded in 1995 and headquartered in Kaohsiung, specializing in the production and sale of health foods primarily in Taiwan and Mainland China. Its core product portfolio includes nutritional health products such as softshell turtle food; dairy products; miscellaneous food items including softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; as well as supplements like terrapin capsules, probiotics, lutein and gac fruit capsules, sesamin and GABA capsules, fish oil capsules, collagen and NMN powder, Vitazyme and postbiotics jelly, calcium and natto extract powder, undenatured type II collagen capsules, and antrodia cinnamomea mycelia essence extract. The company also operates an insurance brokerage segment and is involved in the wholesale of nonalcoholic beverages, candy, baked goods, supplementary food, groceries, daily commodities, cosmetics, and the production of water purification equipment and related parts. Jia Jie Biomedical also engages in the development and production of aquatic product technology and biological products. Significant recent developments include the company’s continuation of strategic funding support within its group, notably providing TWD 97 million to Jia Jie Investment Co., Ltd. in 2024, and its establishment of a Sustainability Development Committee in late 2024, signaling a focus on corporate responsibility and sustainable business practices. The company also maintains its dual operational segments—Nutritional Health Products and Insurance Brokerage—while supporting cross-border trade activities including import, export, distribution, bidding, and quotation of its products, enhancing its market presence. The company underwent a corporate name change in June 2019 from Murad Chia Jei Biotechnology Co., Ltd. to its current name, confirming a strategic rebranding to align with its biomedical and health product focus. Jia Jie Biomedical targets health-conscious consumers and the broader nutritional supplement market in Greater China, maintaining its presence through diverse product lines and emerging sustainability initiatives.